Pradaxa 75mg capsule is used in:

• Prevention and treatment of blood clots

Pradaxa 75mg capsule, as an anticoagulant, exerts its therapeutic effects by inhibiting the activity of thrombin, a key enzyme in the blood clotting process. By doing so, it helps prevent the formation of blood clots, reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Additionally, it is effective in the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Pradaxa 75mg capsule, reducing effectiveness by causing undesirable side effects.

• Store at room temperature, between 20°C to 25°C (68°F to 77°F).
• Keep away from moisture, heat, and light.
• It should not be frozen.
• Keep away from children and pets.

To use Pradaxa 75mg capsule effectively, follow your healthcare provider's prescribed instructions. Typically, it comes in capsule form and should be taken orally, with or without food, as directed. Swallow the capsule whole with a full glass of water to ensure proper absorption. Avoid breaking, crushing, or chewing the capsules, as it may interfere with the medication's effectiveness. The dosage and frequency of administration will depend on your medical condition, such as atrial fibrillation or deep vein thrombosis, and your health status. 

Pradaxa 75mg capsule causes some side effects like all medications, although not everyone will experience them. 

Serious:

• Severe allergic reactions, including rash, itching, swelling, severe dizziness, or difficulty breathing
• Severe bleeding
• Liver problems
• Stroke or embolism

Common:

• Upset stomach or indigestion
• Heartburn
• Nausea
• Diarrhea
• Mild bleeding, such as nosebleeds or bleeding gums
• Bruising more easily than usual

Advice regarding Pradaxa 75mg capsule is to always consult with a healthcare professional before starting or making any changes to your medication regimen. They can assess your medical history, evaluate potential risks and benefits, provide personalized guidance, and monitor your progress throughout treatment. Additionally, closely follow the instructions and recommendations your healthcare provider gives, promptly report any unusual or concerning symptoms, and communicate openly about any concerns or questions you may have. 

Precautions should be taken when using this medication in patients with liver or kidney impairment, as dosage adjustments or special monitoring may be required. Be vigilant for any signs of bleeding, such as unusual bruising, nosebleeds, or blood in urine or stools, and promptly inform your healthcare provider if you experience any of these symptoms. Avoid discontinuing the medication without medical advice, as sudden cessation may increase the risk of stroke. Before any medical procedures or surgeries, inform all healthcare providers about your use. Pregnant and breastfeeding individuals should consult with healthcare professionals before using this medication. Your healthcare professional is the best resource for ensuring safe and effective medication use.

1. Spinler Sarah; The pharmacology and therapeutic use of Dabigatran etexilate
2. ; Journal of Clinical Pharmacology 2013; [Accessed on 24th July 2023], https://pubmed.ncbi.nlm.nih.gov/23400738/
3. KP Garnock Jones; Dabigatran etexilate: A review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation; American Journal of Cardiovascular Drugs: drugs, devices and other inventions 2011; [Accessed on 24th July 2023], https://pubmed.ncbi.nlm.nih.gov/21265583/
4. Boehringer Ingelheim Ltd; Electronic Medicines Compendium; [Revised: May 2020] [Accessed on 24th July 2023], https://www.medicines.org.uk/emc/files/pil.4703.pdf
5. Boehringer Ingelheim Pharmaceuticals, Inc, US Food and Drug Administration, [Revised on Nov 2011], [Accessed on 24th July 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022512s007lbl.pdf